Cargando…
Scaling‐down biopharmaceutical production processes via a single multi‐compartment bioreactor (SMCB)
Biopharmaceutical production processes often use mammalian cells in bioreactors larger than 10,000 L, where gradients of shear stress, substrate, dissolved oxygen and carbon dioxide, and pH are likely to occur. As former tissue cells, producer cell lines such as Chinese hamster ovary (CHO) cells sen...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9815078/ https://www.ncbi.nlm.nih.gov/pubmed/36619888 http://dx.doi.org/10.1002/elsc.202100161 |
_version_ | 1784864275402063872 |
---|---|
author | Gaugler, Lena Mast, Yannic Fitschen, Jürgen Hofmann, Sebastian Schlüter, Michael Takors, Ralf |
author_facet | Gaugler, Lena Mast, Yannic Fitschen, Jürgen Hofmann, Sebastian Schlüter, Michael Takors, Ralf |
author_sort | Gaugler, Lena |
collection | PubMed |
description | Biopharmaceutical production processes often use mammalian cells in bioreactors larger than 10,000 L, where gradients of shear stress, substrate, dissolved oxygen and carbon dioxide, and pH are likely to occur. As former tissue cells, producer cell lines such as Chinese hamster ovary (CHO) cells sensitively respond to these mixing heterogeneities, resulting in related scenarios being mimicked in scale‐down reactors. However, commonly applied multi‐compartment approaches comprising multiple reactors impose a biasing shear stress caused by pumping. The latter can be prevented using the single multi‐compartment bioreactor (SMCB) presented here. The exchange area provided by a disc mounted between the upper and lower compartments in a stirred bioreactor was found to be an essential design parameter. Mimicking the mixing power input at a large scale on a small scale allowed the installation of similar mixing times in the SMCB. The particularities of the disc geometry may also be considered, finally leading to a converged decision tree. The work flow identifies a sharply contoured operational field comprising disc designs and power input to install the same mixing times on a large scale in the SMCB without the additional shear stress caused by pumping. The design principle holds true for both nongassed and gassed systems. |
format | Online Article Text |
id | pubmed-9815078 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98150782023-01-05 Scaling‐down biopharmaceutical production processes via a single multi‐compartment bioreactor (SMCB) Gaugler, Lena Mast, Yannic Fitschen, Jürgen Hofmann, Sebastian Schlüter, Michael Takors, Ralf Eng Life Sci Research Articles Biopharmaceutical production processes often use mammalian cells in bioreactors larger than 10,000 L, where gradients of shear stress, substrate, dissolved oxygen and carbon dioxide, and pH are likely to occur. As former tissue cells, producer cell lines such as Chinese hamster ovary (CHO) cells sensitively respond to these mixing heterogeneities, resulting in related scenarios being mimicked in scale‐down reactors. However, commonly applied multi‐compartment approaches comprising multiple reactors impose a biasing shear stress caused by pumping. The latter can be prevented using the single multi‐compartment bioreactor (SMCB) presented here. The exchange area provided by a disc mounted between the upper and lower compartments in a stirred bioreactor was found to be an essential design parameter. Mimicking the mixing power input at a large scale on a small scale allowed the installation of similar mixing times in the SMCB. The particularities of the disc geometry may also be considered, finally leading to a converged decision tree. The work flow identifies a sharply contoured operational field comprising disc designs and power input to install the same mixing times on a large scale in the SMCB without the additional shear stress caused by pumping. The design principle holds true for both nongassed and gassed systems. John Wiley and Sons Inc. 2022-03-14 /pmc/articles/PMC9815078/ /pubmed/36619888 http://dx.doi.org/10.1002/elsc.202100161 Text en © 2022 The Authors. Engineering in Life Sciences published by Wiley‐VCH GmbH. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Gaugler, Lena Mast, Yannic Fitschen, Jürgen Hofmann, Sebastian Schlüter, Michael Takors, Ralf Scaling‐down biopharmaceutical production processes via a single multi‐compartment bioreactor (SMCB) |
title | Scaling‐down biopharmaceutical production processes via a single multi‐compartment bioreactor (SMCB) |
title_full | Scaling‐down biopharmaceutical production processes via a single multi‐compartment bioreactor (SMCB) |
title_fullStr | Scaling‐down biopharmaceutical production processes via a single multi‐compartment bioreactor (SMCB) |
title_full_unstemmed | Scaling‐down biopharmaceutical production processes via a single multi‐compartment bioreactor (SMCB) |
title_short | Scaling‐down biopharmaceutical production processes via a single multi‐compartment bioreactor (SMCB) |
title_sort | scaling‐down biopharmaceutical production processes via a single multi‐compartment bioreactor (smcb) |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9815078/ https://www.ncbi.nlm.nih.gov/pubmed/36619888 http://dx.doi.org/10.1002/elsc.202100161 |
work_keys_str_mv | AT gauglerlena scalingdownbiopharmaceuticalproductionprocessesviaasinglemulticompartmentbioreactorsmcb AT mastyannic scalingdownbiopharmaceuticalproductionprocessesviaasinglemulticompartmentbioreactorsmcb AT fitschenjurgen scalingdownbiopharmaceuticalproductionprocessesviaasinglemulticompartmentbioreactorsmcb AT hofmannsebastian scalingdownbiopharmaceuticalproductionprocessesviaasinglemulticompartmentbioreactorsmcb AT schlutermichael scalingdownbiopharmaceuticalproductionprocessesviaasinglemulticompartmentbioreactorsmcb AT takorsralf scalingdownbiopharmaceuticalproductionprocessesviaasinglemulticompartmentbioreactorsmcb |